clinical trial · NCT05840952
A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558
COVID-19ALG-097558PlaceboMidazolamItraconazoleCarbamazepineALG-097558 in solution formulationALG-097558 in tablet formulation
brief summary
A multi-part study of ALG-097558 to evaluate safety, tolerability, pharmacokinetics and drug-drug interaction potential after single and multiple doses in healthy volunteers
started
Jul 4, 2023
primary completion
Apr 29, 2024
completion
Apr 29, 2024
last updated
Apr 8, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol